Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on developing targeted therapies, including antibody-drug conjugates, for cancer patients who do not respond to, or have disease progression on, current treatments. The NXTC news feed highlights company announcements that trace the progress of its pipeline and corporate strategy.
Investors and followers of NextCure can use this page to review updates on its lead ADC programs, SIM0505 and LNCB74. News items include business updates and quarterly financial results, where the company discusses clinical trial status, dose escalation progress and plans for proof-of-concept data readouts in advanced solid tumors. Press releases also cover preclinical findings for programs such as NC605 in osteogenesis imperfecta and NC181 in Alzheimer’s disease models.
NXTC news frequently addresses strategic partnerships and licensing agreements, such as the collaboration with Simcere Zaiming for SIM0505 and the co-development arrangement with LigaChem Biosciences Inc. for LNCB74. Readers will also find coverage of scientific presentations at major conferences, including trial-in-progress posters and preclinical data presentations.
In addition, the feed includes capital markets and corporate developments reported by NextCure, such as private placements of common stock and pre-funded warrants, reverse stock split implementation, and changes in executive leadership. These disclosures provide context on how the company finances its research and manages its listing on the Nasdaq Global Select Market.
By reviewing the NXTC news page regularly, users can follow the evolution of NextCure’s oncology-focused pipeline, its non-oncology preclinical efforts, and key corporate decisions that may influence the company’s development plans and financial position.
NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will hold a Virtual Oncology Pipeline Update Event on November 15, 2021, at 4:30 p.m. ET. The event aims to provide insights into its oncology pipeline, including data from the Society for Immunotherapy of Cancer’s 36th Annual Meeting. Dr. Roy Herbst will address unmet needs in lung cancer treatment. Participants can join via conference call or webcast, with a replay available for 30 days after the event.
NextCure, Inc. (Nasdaq: NXTC) appointed Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB) while Ethan Shevach, M.D., retires. These new members bring extensive experience in oncology and immunology, crucial for advancing NextCure's clinical programs. Dr. Jaffee focuses on immune-based therapies, Dr. Matulonis on targeted therapies for gynecologic cancers, and Dr. Zou on cancer immunology. NextCure aims to enhance its capabilities in developing first-in-class immunomedicines.
NextCure, a clinical-stage biopharmaceutical company, announced the publication of preclinical data in Frontiers in Immunology regarding NC410, a first-in-class immunomedicine. The study indicates that collagen fragments in cancer can suppress T cell activity via LAIR-1, but this effect can be reversed by LAIR-2 and NC410. Currently in a Phase 1/2 clinical trial for advanced solid tumors, NC410 aims to provide a new therapeutic option for patients resistant to existing immunotherapies. Initial clinical data will be shared at a conference in November.
NextCure, Inc. (Nasdaq: NXTC) announced the appointment of Dr. Ellen G. Feigal and Dr. Anne Borgman to its Board of Directors, bringing extensive experience in clinical and biopharmaceutical sectors. This change follows the resignation of Dr. Stella Xu. Dr. Feigal specializes in biologics and oncology, while Dr. Borgman has leadership experience in hematology and oncology drug development. Both appointments aim to support NextCure's ongoing clinical programs and the advancement of new immunomedicines for cancer treatment.
NextCure (Nasdaq: NXTC) announced new data presentation from clinical studies on NC318 and NC410 at the Society for Immunotherapy of Cancer meeting from November 10-14, 2021. NC318 targets Siglec-15 to treat advanced solid tumors, while NC410 is focused on blocking LAIR-1 to enhance immune response. Oral presentations will highlight NC318’s clinical benefits, with poster sessions discussing NC410’s safety, tolerability, and immune modulation. Both drugs aim to address unmet needs in cancer therapy, showcasing NextCure's potential in developing innovative immunomedicines.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. The presentation will be pre-recorded and available via an audio webcast on the company’s website, with replays accessible for 30 days post-event. NextCure is focused on developing novel immunomedicines aimed at treating cancer and immune-related diseases, particularly for patients not responding to current therapies. Their proprietary FIND-IO™ platform facilitates research into immune cell targets.
NextCure, a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer, announced its participation in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 PM ET. Investors can access a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company uses its FIND-IO™ platform to discover immune cell targets, aiming to provide new therapies for patients unresponsive to current treatments.
NextCure, Inc. (Nasdaq: NXTC) reported its Q2 2021 financial results, showcasing progress in clinical trials, including the NC318 Phase 2 monotherapy trial. Key updates include resumed enrollment in NSCLC adenocarcinoma and a revised dosing regimen aimed at enhancing drug exposure. Financially, cash and equivalents decreased to $249.5 million, while net loss rose to $18.0 million due to increased operational costs. The company anticipates data updates from ongoing trials and expects its funds to last through the second half of 2023.
NextCure, Inc. (Nasdaq: NXTC) has commenced a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody targeting advanced solid tumors. Michael Richman, CEO, affirmed this trial extends their innovative immunomedicine pipeline for cancers inadequately treated by existing therapies. The trial evaluates NC762's safety and tolerability, with initial data expected by mid-2022. NC762 aims to inhibit tumor growth through a unique mechanism, with applications across several cancer types, including non-small cell lung cancer.
NextCure has published preclinical data on NC410, a novel immunomedicine targeting collagen-rich tumors, in the journal eLife. This treatment, currently in a Phase 1/2 clinical trial for advanced solid tumors, aims to block immune suppression via LAIR-1. Preclinical studies show that NC410 promotes T cell activity and may be effective as a monotherapy or in combination with checkpoint inhibitors. Initial clinical data is expected in the second half of 2021, offering potential hope for patients with resistant cancers.